Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers formulated a topical gel containing β-sitosterol for alopecia treatment and found it demonstrated good 5 alpha reductase inhibitory activity in vitro, comparable to a commercial product, indicating its potential for further antiandrogenic activity investigation.

This study found that the synthetic retinoid EC23 effectively induces keratinocyte hyperproliferation and enhances hair growth in mice, showing more potency than all-trans retinoic acid.

This article reviews anthralin's pharmacology, mode of action, and its use for psoriasis and other dermatoses, but reports no new clinical results.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

Two women had skin reactions from a hair loss treatment and got better after stopping use.

This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.

This study found that a transdermal drug delivery system using nanostructured lipid carriers and polymeric microneedles for β-sitosterol significantly enhanced hair growth in testosterone-induced alopecia rats, suggesting potential for treating androgenic alopecia.

In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.

In this study, the use of Selencin, both in tablet and peptide lotion form, over two months showed significant improvements in reducing hair loss and restoring hair structure and volume in patients with diffuse alopecia, with effects persisting up to four months after treatment.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This study found that intralesional triamcinolone acetonide injections effectively increased hair density in African American women with traction alopecia, showing promise as a safe treatment option.

This study developed innovative silica/natural polysaccharide hybrid nanoparticles encapsulating plant-derived 5-alpha-reductase inhibitors, reporting effective controlled release at hair follicle pH and lower cytotoxicity, suggesting a promising delivery system for antiandrogenic treatments.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

In this article, the authors detail their experience with AltrenoTM, a new topical retinoid lotion used for treating mild to moderate acne, reporting clinical effectiveness and satisfactory tolerability among patients of various ages, including children as young as 9.

This study found that the topical application of DA-OTC-002, a combination of synephrine and tyramine hydrochloride, significantly reduced immediate hair shedding in women by 62.5% compared to a placebo, without any observed adverse effects.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

This study observed that minimal doses of the arotinoid RO 13-6298 successfully treated two cases of severe psoriasis and psoriatic arthritis unresponsive to traditional therapies, despite some side effects.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study found that Solanum nigrum L. extracts showed potential as 5 alpha-reductase inhibitors, similar to finasteride, and highlighted their promise for treating androgenic diseases like benign prostatic hyperplasia and male pattern hair loss.

This research found that liquid-state liposomes and niosomes may enhance finasteride delivery to pilosebaceous units in hamsters more effectively than gel-state vesicles or hydroalcoholic solution.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

In this study, the researchers reported that while both propylene glycol and sodium lauryl sulfate enhanced finasteride's skin deposition, ethanol was the only effective enhancer of finasteride's permeation through the skin.

In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.